Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:25 2024-09-17 am EDT			5-day change	1st Jan Change
266.20 ^CHF	+0.80%		-1.00%	+8.88%

Sep. 16	Mindpeak Announces Collaboration with Roche to Enhance Cancer Diagnostics Through AI	CI
Sep. 16	Swiss Market Index Closes in Red; Roche Slips	MT

ROCHE HOLDINGS AG : JP Morgan keeps a Sell rating

August 01, 2024 at 09:37 am EDT

Richard Vosser from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price is increased from CHF 210 to CHF 220.

Latest news about Roche Holding AG

Mindpeak Announces Collaboration with Roche to Enhance Cancer Diagnostics Through AI	Sep. 16	CI
Swiss Market Index Closes in Red; Roche Slips	Sep. 16	MT
Poseida Gets Regenerative Medicine Advanced Therapy Designation for Myeloma Treatment; Shares Rise	Sep. 16	MT
Roche: Ocrevus Zunovo approved by the FDA	Sep. 16	CF
ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	Sep. 16	ZD
ROCHE HOLDINGS AG : UBS remains Neutral	Sep. 16	ZD
US FDA Approves Roche's Subcutaneous Injection for Multiple Sclerosis	Sep. 16	MT
FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	Sep. 13	MT
Roche Gets FDA Approval for Multiple-Sclerosis Treatment	Sep. 13	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis	Sep. 13	CI
Swiss Market Index Joins Regional Rally in Europe	Sep. 13	MT
Transcript : Roche Holding AG - Shareholder/Analyst Call	Sep. 13
A central bank and it's off again?	Sep. 13
ROCHE : Bank of America raises its recommendation to 'buy	Sep. 13	CF
Deutsche Bank Downgrades Roche to Sell, Cuts PT	Sep. 13	MT
ROCHE : Deutsche Bank downgrades its recommendation to 'sell	Sep. 13	CF
ROCHE HOLDINGS AG : Deutsche Bank lowers its rating to Sell	Sep. 13	ZD
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	Sep. 13	MT
Roche: FDA approves Tecentriq Hybreza	Sep. 13	CF
Roche Obtains US FDA Approval for Tecentriq Hybreza Subcutaneous Cancer Immunotherapy	Sep. 13	MT
FDA Approves Roche?s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy	Sep. 13	CI
Genentech Receives FDA Approval for Cancer Treatment	Sep. 12	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza? With ENHANZE® for Multiple Types of Cancer	Sep. 12	CI
Roche: collaboration agreement with Qritive in AI	Sep. 12	CF
ECB to cut rates without lowering its guard	Sep. 12

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

2024-09-30 - Investor Day

More about the company